Data / Drug companies / Nicardipine hydrochloride
Nicardipine hydrochloride: 27 companies and 52 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Nicardipine hydrochloride is listed in the FDA National Drug Code Directory by 27 companies, with 52 products in commercial distribution. 39 of the products (75.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection; injection, solution; capsule, and the newest product started marketing on October 1, 2026.
The request: Get every company that lists nicardipine hydrochloride in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 27
- Products
- 52
- Generic (ANDA) products
- 39 (75.0%)
- Application numbers
- 19
- Routes
- Intravenous, Oral
- Brand names
- Cardene IV, Cardene IV
- openFDA record search
- api.fda.gov
Companies that list nicardipine hydrochloride
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Baxter Healthcare Corporation | 7 | injection, solution | New drug applications (NDA) | January 30, 1992 |
| Hikma Pharmaceuticals USA Inc. | 5 | injection | New drug applications (NDA) | April 7, 2016 |
| Fresenius Kabi USA, LLC | 3 | injection | Generic drugs (ANDA) | October 1, 2026 |
| Amerisyn LLC | 2 | capsule | Generic drugs (ANDA) | July 26, 2026 |
| Amici Pharma, Inc. | 2 | capsule | Generic drugs (ANDA) | January 15, 2026 |
| Ani Pharmaceuticals, Inc. | 2 | capsule | Generic drugs (ANDA) | June 25, 2021 |
| Bionpharma Inc. | 2 | capsule | Generic drugs (ANDA) | November 4, 2024 |
| Burel Pharmaceuticals, LLC | 2 | capsule | Generic drugs (ANDA) | January 8, 2023 |
| Caplin Steriles Limited | 2 | injection | Generic drugs (ANDA) | June 25, 2026 |
| Cipla USA Inc. | 2 | injection | Generic drugs (ANDA) | October 2, 2024 |
| Epic Pharma, LLC | 2 | capsule | Generic drugs (ANDA) | May 5, 2010 |
| Eugia US LLC | 2 | injection, solution | Generic drugs (ANDA) | April 8, 2021 |
| Glenmark Pharmaceuticals Inc., USA | 2 | capsule | Generic drugs (ANDA) | December 16, 2022 |
| Puracap Laboratories LLC DBA Blu Pharmaceuticals | 2 | capsule | Generic drugs (ANDA) | December 15, 2016 |
| Somerset Therapeutics, LLC | 2 | injection | Generic drugs (ANDA) | April 20, 2026 |
| WG Critical Care, LLC | 2 | injection, solution | Generic drugs (ANDA) | July 10, 2025 |
| American Regent, Inc. | 1 | injection, solution | Generic drugs (ANDA) | May 8, 2020 |
| Archis Pharma LLC | 1 | injection, solution | Generic drugs (ANDA) | December 7, 2024 |
| Armas Pharmaceuticals Inc. | 1 | injection | Generic drugs (ANDA) | April 3, 2024 |
| Chengdu Shuode Pharmaceutical Co., Ltd | 1 | injection | Generic drugs (ANDA) | September 11, 2024 |
| Civica, Inc. | 1 | injection, solution | Generic drugs (ANDA) | October 29, 2020 |
| HF Acquisition Co LLC, DBA HealthFirst | 1 | injection | New drug applications (NDA) | February 1, 2020 |
| Lifestar Pharma LLC | 1 | injection | Generic drugs (ANDA) | February 24, 2026 |
| Meitheal Pharmaceuticals Inc. | 1 | injection, solution | Generic drugs (ANDA) | August 20, 2025 |
| Micro Labs Limited | 1 | injection | Generic drugs (ANDA) | November 1, 2023 |
| Qilu Pharmaceutical Co., Ltd. | 1 | injection, solution | Generic drugs (ANDA) | October 28, 2025 |
| Sagent Pharmaceuticals | 1 | injection, solution | Generic drugs (ANDA) | January 1, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 19 | 36.5% |
| Injection, solution | 17 | 32.7% |
| Capsule | 16 | 30.8% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 39 | 75% |
| New drug applications (NDA) | 13 | 25% |
Pharmacologic classes
| Class | Products |
|---|---|
| Dihydropyridine Calcium Channel Blocker | 52 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.